Revolo completes patient enrollment in phase 2 trial of ‘1104 in eosinophilic esophagitis: New Orleans Wednesday, September 14, 2022, 14:30 Hrs [IST] Revolo Biotherapeutics (Rev ...
Title: IRL201104, A Novel Immunomodulatory Peptide, shows efficacy through the sublingual and subcutaneous routes in an allergen driven model of Atopic Dermatitis Presenter: Dr. Jorge De Alba, Vice ...
Dr. De Alba will discuss preclinical studies that show the potential of the Company’s lead clinical asset, ‘1104, for treating atopic dermatitis (AD). In a chronic allergen-driven murine model of AD, ...
NEW ORLEANS and LONDON, April 15, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior ...
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced its decision to accelerate the advancement of a sublingual, ...
In multiple preclinical models evaluated in single-dose toxicity studies, there were no ‘1104-related local tolerability adverse effects after treatment with the ‘1104 SQ formulation at dose levels ...
Data continues to demonstrate the broader potential of ‘1104 to avoid and reduce inflammation in multiple models of disease, including allergy and beyond NEW ORLEANS and CAMBRIDGE, UK,, May 22, 2023 ...
NEW ORLEANS and CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve ...
Data continues to differentiate '1104 as a potential allergic disease treatment that acts upstream in the immune cascade '1104 reduces key indices of skin inflammation and inflammatory mediators in a ...
The MarketWatch News Department was not involved in the creation of this content. GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited ...
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited ("Revolo”) today announced that it will present a poster on its lead candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results